Product Description
Polymyxins comprise a class of antibiotics targeting gram-negative bacterial infections. Polymyxin B and Polymyxin E (colistin) are the two drugs within this antibiotic class used primarily in clinical practice. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557540/)
Mechanisms of Action: Cell Wall Inhibitor,Bacterial Growth Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | Estonia | France | Germany | Hong Kong | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Slovenia | South Africa | Spain | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Taiwan
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Pneumonia, Bacterial|Pneumonia, Ventilator-Associated
Phase 1: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-002856-37 | P2 |
Active, not recruiting |
Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
2024-05-25 |
|
| TTYPX2201 | P1 |
Completed |
Kidney Diseases |
2023-03-03 |
21% |